key: cord-0985069-yinweejd
authors: Sharma, Anuj
title: It is too soon to attribute ADE to COVID-19
date: 2020-04-05
journal: Microbes Infect
DOI: 10.1016/j.micinf.2020.03.005
sha: 07849c55a82b791e3dc2722f6d1329bdf84532ad
doc_id: 985069
cord_uid: yinweejd

nan

In the article "Is COVID-19 receiving ADE from other coronaviruses?" author has suggested the possibility of antibody dependent enhancement (ADE) of SARS-COV-2 disease (COVID-19) as a potential mechanism of the increase in severity of the disease [1] . Although it's an interesting hypothesis, we should be careful in attributing ADE to enhanced severity of the current disease. As viruses from same group share cross reactivity, it is not uncommon to have cross reactive antibody responses [2] . Outside of the dengue virus serotypes family, which has demonstrated ADE in animal models, the ADE of the viruses using sub-neutralizing antibody levels has largely been restricted to in-vitro experiments. Cell culture experiments are considered pre-requisite to moving forward to animal experiments, however, not always result is translated to in-vivo setup. There is lack of collective innate/adaptive immune response in-vitro, which is presented in-vivo and the intricate interactions drive the disease pathology. Deliberate reduction in the neutralizing antibody levels in in-vitro assays and lack of innate immune response from other cells may result in an artificial ADE in cell-culture. As COVID-19 spread across the globe a common pattern of underlying morbid conditions such as diabetes and cardiovascular conditions is appearing. Such underlying conditions are known to present immune response dysfunction [3, 4] . As reported by Channappanavar et al., immune dysregulation may contribute to lethal pneumonia induction by SARS-CoV [5] . To date, vaccines are the most effective way of protecting against infectious diseases.

Improper attribution of ADE in the absence of robust demonstration in animal models may hinder/scuttle the efforts to develop effective vaccines against SARS-CoV-2 and or other viruses of human health importance.

Opinions expressed herewith are those of the author and are not necessarily representative of those of the USUHS, DoD, or the United States Army, Navy or Air Force.

Is COVID-19 receiving ADE from other coronaviruses? Microbes Infect

Sero-prevalence and cross-reactivity of chikungunya virus specific anti-E2EP3 antibodies in arbovirus-infected patients

Diabetic complications and dysregulated innate immunity

Stress and inflammation in coronary artery disease: a review Psychoneuroendocrineimmunology-based

Dysregulated type I interferon and inflammatory monocyte-macrophage responses cause lethal pneumonia in SARS-CoV-infected mice

Author declares no conflict of interest.